尊龙凯时
Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Process and Analytical Method Development
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Announcements and Circulars
The Listed Files
Financial Reports and ESG Reports
Company Promotion Materials
Investor Relations Query
Investor Relations Journal
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of TOT
Join in TOT
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
＜
News & Events
News & Events
News
Events
Media Attention
Partner News
2022
2019
2020
2021
2022
2023
2022.12
26
CDMO transformation and upgrading proved effective, TOT BIOPHARM-B (1875.HK) embraces opportunities prospective strategic adjustment
2022.09
09
TOT BIOPHARM-B (1875.HK) releases quality growth potential steadily, cash flows from operating activities turned positive for the first time!
2022.08
31
ADC heat brings new opportunities, lack of professional CDMO supplier triggers capacity battle
«
1
»
The module is under construction
【网站地图】
【sitemap】